Is Tempus AI the Future of Healthcare Investing?
Tempus AI stock has been attracting a lot of attention lately, and we can see why. The stock offers exposure to AI in a way that's set to transform the healthcare industry. Tempus sells genetic tests, captures data from those tests, then licenses that data to pharmaceutical companies, collecting fees on it for years to come. The business model is a lucrative one, attracted attention from ARK Invest's Cathie Wood herself. We don't invest based on hype, so today we'll analyze TEM stock to see if it's a buy now.
Stay informed with our free disruptive technology investing newsletter, Nanalyze…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.